Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor

Xin Zheng,1 Song Li,1 Wei-hua Zhang,2 Hui Yang1 1Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China; 2Department of Biology and Biochemistry, University of Houston, Houston, TX, USA Abstract: Metabolic a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zheng X, Li S, Zhang WH, Yang H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6a334831f80d4fd9ae6a143474eefe3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a334831f80d4fd9ae6a143474eefe3e
record_format	dspace
spelling	oai:doaj.org-article:6a334831f80d4fd9ae6a143474eefe3e2021-12-02T00:20:51ZMetabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor1178-7007https://doaj.org/article/6a334831f80d4fd9ae6a143474eefe3e2015-08-01T00:00:00Zhttp://www.dovepress.com/metabolic-abnormalities-in-pituitary-adenoma-patients-a-novel-therapeu-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Xin Zheng,1 Song Li,1 Wei-hua Zhang,2 Hui Yang1 1Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China; 2Department of Biology and Biochemistry, University of Houston, Houston, TX, USA Abstract: Metabolic abnormalities are common in cancers, and targeting metabolism is emerging as a novel therapeutic approach to cancer management. Pituitary adenoma (PA) is a type of benign tumor. Impairment of tumor cells' metabolism in PA seems not to be as apparent as that of other malignant tumor cells; however, aberrant hormone secretion is conspicuous in most PAs. Hormones have direct impacts on systemic metabolism, which in turn, may affect the progression of PA. Nowadays, conventional therapeutic strategies for PA do not include modalities of adjusting whole-body metabolism, which is most likely due to the current consideration of the aberrant whole-body metabolism of PA patients as a passive associated symptom and not involved in PA progression. Because systemic metabolic abnormalities are presented by 22.3%–52.5% PA patients and are closely correlated with disease progression and prognosis, we propose that assessment of metabolic status should be emphasized during the treatment of PA and that control of metabolic abnormalities should be added into the current therapies for PA. Keywords: metabolic abnormalities, pituitary adenoma, therapeutic target, prognostic factor Zheng XLi SZhang WHYang HDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 357-361 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Zheng X Li S Zhang WH Yang H Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
description	Xin Zheng,1 Song Li,1 Wei-hua Zhang,2 Hui Yang1 1Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China; 2Department of Biology and Biochemistry, University of Houston, Houston, TX, USA Abstract: Metabolic abnormalities are common in cancers, and targeting metabolism is emerging as a novel therapeutic approach to cancer management. Pituitary adenoma (PA) is a type of benign tumor. Impairment of tumor cells' metabolism in PA seems not to be as apparent as that of other malignant tumor cells; however, aberrant hormone secretion is conspicuous in most PAs. Hormones have direct impacts on systemic metabolism, which in turn, may affect the progression of PA. Nowadays, conventional therapeutic strategies for PA do not include modalities of adjusting whole-body metabolism, which is most likely due to the current consideration of the aberrant whole-body metabolism of PA patients as a passive associated symptom and not involved in PA progression. Because systemic metabolic abnormalities are presented by 22.3%–52.5% PA patients and are closely correlated with disease progression and prognosis, we propose that assessment of metabolic status should be emphasized during the treatment of PA and that control of metabolic abnormalities should be added into the current therapies for PA. Keywords: metabolic abnormalities, pituitary adenoma, therapeutic target, prognostic factor
format	article
author	Zheng X Li S Zhang WH Yang H
author_facet	Zheng X Li S Zhang WH Yang H
author_sort	Zheng X
title	Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
title_short	Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
title_full	Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
title_fullStr	Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
title_full_unstemmed	Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
title_sort	metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/6a334831f80d4fd9ae6a143474eefe3e
work_keys_str_mv	AT zhengx metabolicabnormalitiesinpituitaryadenomapatientsanoveltherapeutictargetandprognosticfactor AT lis metabolicabnormalitiesinpituitaryadenomapatientsanoveltherapeutictargetandprognosticfactor AT zhangwh metabolicabnormalitiesinpituitaryadenomapatientsanoveltherapeutictargetandprognosticfactor AT yangh metabolicabnormalitiesinpituitaryadenomapatientsanoveltherapeutictargetandprognosticfactor
_version_	1718403805564895232

Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor

Ejemplares similares